[Related-factor analysis on efficacy of re-platinum chemotherapy in platinum-sensitive recurrent ovarian carcinoma].
OBJECTIVE
To analysis the related factors of efficacy of re-platinum chemotherapy in platinum-sensitive recurrent ovarian carcinoma.


METHODS
Forty-one patients with platinum-sensitive recurrent ovarian cancer from Jan. 1998 to Oct. 2002 were reviewed, 37 factors were analyzed, including age, the optimal of primary surgery, number of chemotherapy cycles, standard chemotherapy or not, serum CA(125) level, follow up or not, relapse interval, the site and the number of relapse lesion, et al.


RESULTS
Response rate of chemotherapy was 56%, the toxicity was not serious. Response rate of standard chemotherapy was 76% (19/25), not standard chemotherapy was 25% (4/16), standard chemotherapy or not was the only factor related to efficacy (P < 0.05).


CONCLUSIONS
Re-platinum chemotherapy to platinum-sensitive recurrent ovarian carcinoma is reasonable, standard chemotherapy or not affects the response rate.
Cheng
Xiao-dong
XD
Department of Gynecological Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.
Lü
Wei-guo
WG
Xie
Xing
X
Huang
Xiu-feng
XF
Ye
Da-feng
DF
He
Hong-cheng
HC
Ding
Zhi-ming
ZM
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016015:Logistic Models; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds